XCUR: Exicure, Inc. Net earnings per share (EPS TTM)
The rolling net income per share dynamics for Exicure, Inc. (XCUR) demonstrate the impact of express oligonucleotide delivery via air channels on financial results, where the -1.31 mark indicates the current state. Margin stability is maintained through strict cold chain control and supplier diversification. The business capitalization relies on the licensing of SNA technology, which enables deep tissue drug delivery through royalties from partners.
Financial and market metric breakdowns for Exicure Corp (XCUR)
- current quotes and average value forecast:
- market capitalization information:
- business book valuation details:
- debt and liquidity details:
- earnings and valuation multiples indicators:
XCUR - Net Income|Future Profit Exicure, Inc.|XCUR - P/E Multiple|Future Price to Earnings Exicure|XCUR - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Exicure|XCUR - Operating profit before amortization|Earnings per share for the last twelve months Exicure|XCUR - Earnings per share for the last 12 months|Quarterly EPS earnings growth exicuretx.com|XCUR - Earnings growth in current year|Earnings growth forecast for next year Exicure, Inc.
- issuer revenue and sales details:
Initial company analysis:Exicure, Inc. - XCUR
The scalable gene therapy model of Exicure, Inc. (XCUR) is reflected in the 12-month rolling earnings per share history. This indicator demonstrates the bottom-line financial result allocated to a single common share. The calculation excludes the impact of issuance volume, highlighting the net efficiency of capital generation. For a biotech company with low synthesis costs for drugs, growth in this value confirms the commercial success of the platform. However, purchasing the asset at a local maximum creates a risk of investment stagnation.
Competitors of Exicure, Inc.
TEM: Net earnings per share for the last 12 months|QGEN (Qiagen Group) - Earnings per share for the last 12 months|Ionis (IONS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Repligen Inc. (RGEN)|RNA (Avidity Biosciences) - Net earnings per share (EPS TTM)|CRSP (CRISPR Therapeutics AG) - Earnings per share for the last four quarters|Earnings per share for the last twelve months GeneDx (WGS)|RARE - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) BEAM (Beam Therapeutics Inc)|Earnings per share for the trailing year SRPT|twistbioscience.com - Net earnings per share (EPS TTM)|Earnings per share for the trailing year TXG (10x Genomics, Inc.)|NTLA: Net earnings per share (EPS TTM)|Earnings per one share for the last 12 months STOK (Stoke Therapeutics, Inc.)|Net earnings per share for the last 12 months BLFS|Net earnings per one share for the last twelve months Wave Pharma WVE|Net earnings per share for the last 12 months MAZE (Maze Tx)|SION - Net earnings per one share for the last twelve months|Prime Medicine - Net earnings per share for the last 12 months|Taysha Gene Therapies Inc (TSHA) - Net earnings per one share for the last twelve months|uniqure.com - Net earnings per share (EPS TTM)|Net earnings per share for the trailing year MeiraGTx Corp (MGTX)|REGENXBIO (RGNX) - Earnings per share for the last twelve months|SLDB - Net earnings per share for the last four quarters|OCGN (ocugen.com) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Pacific Biosciences of California, Inc. PACB|Net earnings per share (EPS TTM) BNTC|Net earnings per share for the last four quarters Design Pharma|Net earnings per share (EPS TTM) RCKT (Rocket Corp)|FDMT - Net earnings per share for the last 12 months|Lexeo - Net earnings per share (EPS TTM)|KRRO - Net earnings per share (EPS TTM)|EDIT: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months SLN|Net earnings per share for the last 12 months PRQR|Net earnings per one share for the last twelve months Codexis CDXS|Earnings per share for the last twelve months Sangamo BioSciences (SGMO)|Net earnings per share (EPS TTM) Nautilus Biotechnology Inc (NAUT)|Net earnings per share (EPS TTM) MGX (Metagenomi Inc.)|Precision BioSciences - Earnings per share for the last twelve months|generationbio.com - Net earnings per share (EPS TTM)|BOLD: Earnings per share for the last twelve months|Imunon, Inc. (IMNN) - Earnings per share for the last twelve months|RXi Pharmaceuticals (PHIO) - Net earnings per share (EPS TTM)|MBIO (Mustang Bio Corp) - Net earnings per share (EPS TTM)|Earnings per share for the last 12 months RNAZ (TransCode Therapeutics)|Net earnings per share (EPS TTM) BNGO|APDN: Earnings per one share for the last 12 months|Net earnings per share (EPS TTM) BLUE (bluebird bio Inc.)|Net earnings per share for the last four quarters ImmunoPrecise Antibodies (IPA)|OMGA: Net earnings per share for the last 12 months|OMIC (Singular Genomics Systems Inc) - Earnings per share for the last 12 months|Regulus Therapeutics (RGLS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months syros.com (SYRS)|TBIO (Telesis Bio Inc.) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months TRACON Pharmaceuticals Inc. (TCON)|Net earnings per share for the last 12 months UBX (Unity Biotechnology, Inc.)
